Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Androgens and estrogens are known to be critical regulators of mammalian physiology and
development. While these two classes of steroids share similar structures (in general …

Cancer proteogenomics promises new insights into cancer biology and treatment efficacy by
integrating genomics, transcriptomics and protein profiling including modifications by mass …

Simple Summary Factors such as estrogen, progesterone, and androgen receptors, also
known as nuclear receptors, are abundantly expressed in the majority of breast cancers …

Breast cancer (BC) is one of the most common malignancies and the leading cause of
cancer-related mortality in women. Androgen receptor (AR) is frequently expressed in …

Background Gastric cancer (GC) is one of the most common malignancies worldwide,
particularly in China. DNA damage‐inducible transcript 4 (DDIT4) is a mammalian target of …

The androgen receptor (AR) is expressed in the majority of breast cancer and across the
three main breast cancer subtypes. Historically, the oncogenic role of AR has best been …

Simple Summary Drug resistance is the “Achilles' heel” in current oncology. In this sense,
the clinical management of HER2 breast carcinomas (tumors with overexpression …

Molecular subtyping of breast cancer is based mostly on HR/HER2 and gene expression-
based immune, DNA repair deficiency, and luminal signatures. We extend this description …

This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with
metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2 …